Neurocrine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. 

CEO
Kyle W. Gano
CEOKyle W. Gano
Employees
2,000
Employees2,000
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1992
Founded1992
Employees
2,000
Employees2,000

NBIX Key Statistics

Market cap
16.94B
Market cap16.94B
Price-Earnings ratio
24.82
Price-Earnings ratio24.82
Dividend yield
—
Dividend yield—
Average volume
1.78M
Average volume1.78M
High today
—
High today—
Low today
—
Low today—
Open price
$169.96
Open price$169.96
Volume
0.00
Volume0.00
52 Week high
$186.12
52 Week high$186.12
52 Week low
$122.14
52 Week low$122.14

Stock Snapshot

As of today, Neurocrine(NBIX) shares are valued at $167.40. The company's market cap stands at 16.94B, with a P/E ratio of 24.82.

On 2026-11-16, Neurocrine(NBIX) shares started trading at $169.96, with intraday highs of — and lows of —.

Trading volume for Neurocrine(NBIX) stock has reached 0, versus its average volume of 1.78M.

The stock's 52-week range extends from a low of $122.14 to a high of $186.12.

The stock's 52-week range extends from a low of $122.14 to a high of $186.12.

NBIX News

TipRanks 3d
Neurocrine Updates Rare Epilepsy Study as NBI-921352 Trial Ends

Neurocrine Biosciences (NBIX) announced an update on their ongoing clinical study. Study Overview: Neurocrine Biosciences’ official Phase 2 study, “A Prospecti...

Simply Wall St 3d
Neurocrine Biosciences Shares Rose Even As Profit Fell

Neurocrine Biosciences spent 2026 talking about concrete moves such as a US$2.9b cash deal for Soleno Therapeutics and fresh data readouts for CRENESSITY and VY...

Neurocrine Biosciences Shares Rose Even As Profit Fell
TipRanks 3d
Neurocrine price target raised to $191 from $185 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $191 from $185 and keeps an Equal Weight rating on the shares. The firm adjusted estimates...

Analyst ratings

86%

of 28 ratings
Buy
85.7%
Hold
14.3%
Sell
0%

More NBIX News

Zacks 6d
NBIX or GRDN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX Quick QuoteNBIX - Free Report)...

NBIX or GRDN: Which Is the Better Value Stock Right Now?
Simply Wall St 6d
Is Neurocrine Biosciences Still Cheap As INGREZZA Data And Earnings Outlook Lift Sentiment?

Fresh data on patient reported outcomes for INGREZZA has pushed Neurocrine Biosciences (NBIX) back into focus for investors, as quality of life metrics intersec...

Is Neurocrine Biosciences Still Cheap As INGREZZA Data And Earnings Outlook Lift Sentiment?
TipRanks 7d
Neurocrine Biosciences Earnings Call Signals Broad Growth

Neurocrine Biosciences ((NBIX)) has held its Q3 earnings call. Read on for the main highlights of the call. Neurocrine Biosciences delivered a strongly positiv...

Zacks 7d
All You Need to Know About Neurocrine Rating Upgrade to Buy

Neurocrine Biosciences (NBIX Quick QuoteNBIX - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy)....

All You Need to Know About Neurocrine Rating Upgrade to Buy

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.